A variety of extraimmune system factors, including hormones, play a critical role in regulating immunity. Progesterone has been shown to affect immunity in rodents and humans, mainly at concentrations commensurate with pregnancy. These effects are primarily mediated via the progesterone receptor (PR), which acts as a transcription factor, although non-genomic effects of PR activation have been reported. In this study, we evaluated the effects of progesterone on rat dendritic cells (DCs) at ranges encompassing physiologic and pharmacologic concentrations to determine whether progesterone plays a role in modulating DC-mediated immune responses. DCs were derived by culturing rat bone marrow cells in granulocyte macrophage colony-stimulating factor and IL-4. Cells were analyzed for expression of PR using FACS analysis, real-time reverse transcriptase-PCR and fluorescent microscopy. Progesterone treatment of LPS-activated, mature bone marrow-derived dendritic cells (BMDCs) suppressed production of the pro-inflammatory response-promoting cytokines tumor necrosis factor-a and IL-1b in a dose-dependent manner but did not affect production of the pro-inflammatory response-inhibiting cytokine IL-10. Treatment of cells with progesterone also resulted in down-regulation of co-stimulatory molecule CD80 and MHC class II molecule RT1B expression. In addition, progesterone inhibited DC-stimulated proliferation of T cells. Suppression of pro-inflammatory response-promoting cytokine production by progesterone was prevented using the PR antagonist RU486. There was no dose-dependent effect of progesterone treatment on immature DC capacity to take up antigenic peptide. These data indicate that progesterone directly inhibits mature rat BMDC capacity to drive pro-inflammatory responses. This mechanism could contribute to or account for some of the differential expression of autoimmune/ inflammatory disease in females.
Introduction
Dendritic cells (DCs) are antigen-presenting cells critical for mounting a potent immune response (1) . They are able to take up antigen as immature DCs, and upon stimulation with maturation agents, these cells secrete large amounts of cytokines to stimulate naive lymphocytes and promote proinflammatory (2), anti-inflammatory (3, 4) or tolerogenic (5, 6) responses. In addition to production of cytokines, mature DCs express high levels of MHC molecules and co-stimulatory molecules (CD80, CD86) on their surface to provide the first and second signals, respectively, that stimulate naive T cells (7) . DCs are also important because of their capacity to influence the type of response elicited by T h cells in the presence of appropriate cytokines (8, 9, 10) or chemokines (11) in the microenvironment. They are thought to be crucial in amelioration of a number of disease states (12) (13) (14) , initiate strong immune responses against pathogens (11, 15) and are being used for development of vaccines (16, 17, 18) . Furthermore, these cells have recently been shown to be important in the development of autoimmune diseases (19) , which have a 2-to 10-fold higher incidence in females compared with males (20) .
Progesterone is produced by the granulosa cells and corpus luteum of the ovary and is important for ovulation (21) , uterine cell activation (22) and mammalian gland development (23) in addition to its essential role in establishment and maintenance of pregnancy (24) . A number of studies have demonstrated that progesterone has immune suppressive properties (25) . It is thought to contribute to susceptibility to HIV in women (26) and has been shown to increase the susceptibility to Chlamydia infection in rats (27) . Progesterone has been shown to have direct effects on T lymphocytes at concentrations consistent with pregnancy, suggesting that it may play a role in preventing maternal immune responses against fetal antigens (28) . It was also shown to increase the number of Langerhans cells in the human vaginal epithelium (29) , although the exact functional nature of these cells was not investigated. A recent study of a subset of DCs, CD83
+ DCs, derived from human decidua of pregnant women, showed an increase in CD83 and HLA-DR expression of these cells when treated with progesterone at levels similar to early pregnancy (30) . Although the functional capacity of these cells was not analyzed in this study, this would suggest a role for progesterone in influencing maturation of these cells. Another recent study investigating the effects of progesterone on mouse DCs showed direct effects on maturation at concentrations commensurate with pregnancy (31) .
While it is important to understand the role that progesterone might play on immunity during pregnancy, it is also necessary to understand the role that this hormone plays at levels associated with non-pregnant states to determine its effects on immune cells that might increase female susceptibility to autoimmune disease. This would seem evident as progesterone is a major hormone in women and the majority of autoimmune diseases disproportionately affect females (20) , suggesting a role for sex hormones in such diseases. There are currently no thorough studies of the effects of progesterone on rat bone marrow-derived dendritic cells (BMDCs). The purpose of this study was to define the effects of progesterone on the function of cultured BMDCs and to determine whether these effects were mediated via the progesterone receptor (PR). Here, we show that progesterone has a profound effect on mature DCs by modulating the ability of these cells to function as stimulators of pro-inflammatory responses at concentrations similar to that seen during the menstrual cycle as well as during pregnancy.
Methods

Animals
Female Fischer (F344/NHsd) rats (8-to 11-weeks old) were obtained from Harlan Sprague Dawley (Indianapolis, IN, USA). Animals were maintained in pathogen-free facilities, and all procedures were performed on approved protocols in accordance with the National Institute of Mental Health (NIMH) Animal Care and Use Committee.
Reagents
Recombinant granulocyte macrophage colony-stimulating factor (rGM-CSF) and recombinant IL-4 (rIL-4) were obtained from PeproTech (Rocky Hill, NJ, USA). FITC-dextran, propidium iodide, LPS from Escherichia coli and RU486 (mifepristone) were purchased from Sigma (St Louis, MO, USA).
Antibodies
Antibodies that recognize and bind to amino acid residues 346-367 of the rat glucocorticoid receptor (GR) (100 lg ml À1 , diluted 1:5000) and amino acid residues 533-547 of the rat PR (100 lg ml À1 , diluted 1:5000) were purchased from Affinity Bioreagents (Golden, CO, USA). Antibodies to rat CD4 (clone OX35) (0.1 mg ml À1 ), CD80 (clone 3H5) (0.1 mg ml À1 ) and MHC class II RT1B (clone OX6) (0.1 mg ml
À1
) were purchased from BD Biosciences (San Diego, CA, USA). Antibodies to rat CD11c (0.2 mg ml À1 ) were obtained from eBioscience (San Diego, CA, USA). Isotype control antibodies included the following: purified mouse IgG (PR control) (0.1 mg ml
, diluted 1:5000) (BD Biosciences); purified rabbit IgG (GR control) (1 mg ml À1 , diluted 1:50 000) (R&D Systems, Minneapolis, MN, USA); mouse IgG1 (CD4, CD80 and RT1B control) (0.1 mg ml À1 ) (BD Biosciences) and Armenian hamster IgG (CD11c control) (0.2 mg ml À1 ) (eBioscience).
Isolation of bone marrow cells
Animals were sacrificed by decapitation to obtain femurs and tibias, which were collected in RPMI 1640 (Mediatech, Herndon, VA, USA) containing 10% charcoal-stripped serum (CSS) (Biomeda, Foster City, CA, USA) and 2% L-glutamine and 2% penicillin-streptomycin (both from Sigma) (henceforth referred to as conditioned medium). CSS was used as a replacement for fetal bovine serum as some components of serum have been shown to demonstrate hormone-mimicking properties. Muscle and connective tissues were removed from the bone, and bone marrow cells were flushed out with PBS (pH 7.4). Bone marrow cells were passed through a 70-lm cell strainer (Becton-Dickinson, San Diego, CA, USA) to remove debris. RBCs were lysed with ACK lysis buffer (BioWhittaker, Walkersville, MD, USA) containing ammonium hydroxide.
Generation of BMDCs
BMDCs were generated as previously described (32) with slight modifications. Briefly, bone marrow cells (10 3 10 6 ) were plated in six-well plates with conditioned medium supplemented with rGM-CSF (20 ng ml À1 ) and rIL-4 (50 ng ml À1 ) (both from PeproTech) at a total volume of 3 ml. On day 2, the medium containing non-adherent cells was removed, and adherent cells were washed with PBS. Fresh conditioned medium with rGM-CSF and rIL-4 was added to each well. Cultures were fed with cytokines in conditioned medium (100 ll total additional volume) again on day 4. By day 5, semi-adherent aggregates of cells had formed. Noted culturing conditions were used for all subsequent experiments.
RNA isolation and real-time reverse transcriptase-PCR
Total RNA from cultured DCs treated with LPS (for maturation) and hormones for 24 h was isolated using Trizol reagent (Invitrogen Life Technologies, Eugene, OR, USA), and further purified through 2-propanol and graded ethanols. RNA was quantified using the NanoDrop Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). cDNA was generated using 200 ng of total RNA per sample in a reverse transcriptase (RT) reaction using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). The RT product was amplified using iQ SYBR Green Supermix (Bio-Rad) with the iQ5 Real-Time PCR Detection System (Bio-Rad). Primer sequences used were the following-18S (Fwd: CCAGTAA-GTGCGGGTCATAAGC, Rev: CCATCCAATCGGTAGTAGCGAC); PR (Fwd: CTTTGTTTCCTCTGCAAAAATTG, Rev: GTATACA-CGTAAGGCTTTCAGAAGG); GR (Fwd: TGATGGGAATGAC-TTGGGC, Rev: TTGGGAAACTCCTTCTCTGTCGGG) and tumor necrosis factor-a (TNF-a) (Fwd: TCTTCTGTCTACTGA-ACTTCGGGG, Rev: ATGGAACTGATGAGAGGGAGCC). The expression of the target gene was normalized with respect to 18S, which served as a control gene. Relative fold induction was determined using the 2 -DDCt method.
Analysis of hormone receptor expression
Immature cultured DCs (1 3 10 6 per tube) were collected in polystyrene Falcon tubes (BD Biosciences) and washed with FACS buffer containing PBS (Molecular Biologicals, Inc., Columbia, MD, USA), 2% CSS (Biomeda) and 0.2% sodium azide (Sigma). Cells were centrifuged for 5 min at 2000 r.p.m. Supernatant was removed from the tubes followed by re-suspension of cells and incubation with 10 ll FITClabeled anti-rat CD11c (eBioscience) and 10 ll PerCPlabeled anti-rat MHC class II RT1B (BD PharMingen, San Diego, CA, USA). Tubes were placed on ice for 30 min to ensure sufficient time for antibody to bind to cells. Cells were washed with FACS buffer to remove excess antibody and centrifuged for 5 min at 2000 r.p.m. Cells were then treated with Cytofix/Cytoperm solution (BD Biosciences) for 20 min to permeabilize cells and washed with Cytofix/Cytoperm wash buffer to remove excess solution. Cells were incubated with 10 ll horse serum for 10 min. Incubation of permeabilized cells with horse serum is a commonly used method for preventing non-specific binding of antibodies to intracellular protein (33) . Ten microliters of purified antibodies to rat PR or GR (both from Affinity Bioreagents) was added for 10 min; separate tubes were incubated with 10 ll purified irrelevant antibodies to mouse IgG and rabbit IgG as isotype controls for PR and GR, respectively. A secondary antibody conjugated to PE was then added for an additional 10 min to each tube. All incubations were done on ice (4°C). Experiments included analysis of only one steroid hormone receptor expressed by cultured cells. Cells were collected using a BD FACSCalibur (BD Biosciences) and analyzed with FlowJo analysis software (Tree Star, Ashland, OR, USA).
Hormone treatment and stimulation of bone marrow cultures
On day 6, cells were treated with varying doses of progesterone or dexamethasone dissolved in 100% ethanol (both from Sigma). Following a 2-h treatment with hormones (to allow sufficient time for hormones to initiate effects on cells prior to maturation), LPS from E. coli (5 lg ml À1 ) was subsequently added to cells. This dose of LPS was determined from previous dose-response experiments in the laboratory (34) and to ensure that a sufficient amount of maturation agent was available for stimulation of immature cells. Cells not treated with LPS (remaining in immature state) were used as a control for maturation. Cells treated with ethanol alone served as a control experiment for treatment of LPSmatured cells with steroid hormones. Some cultures also received the PR and GR antagonist RU486 (10 -8 M) to determine the role of the progesterone or dexamethasone receptor on the effects of progesterone and dexamethasone on cultured cells. Cultures remained incubated up to 48 h at 37°C/5% CO 2 to determine hormonal effects on mature DC function.
Antigen uptake
Immature cells (2.5 3 10 5 per well, four wells per condition) were cultured (as described in Generation of BMDCs) in temperature-sensitive, 96-well RepCellâ plates (CellSeed, Tokyo, Japan) following treatment with varying doses of progesterone associated with menstrual cycle and pregnancy concentrations and 100 ng ml À1 FITC-dextran (Sigma) for 2 h at 37°C/5% CO 2 . Treatment of cells without progesterone or with ethanol alone served as a control experiment for effects of progesterone treatment. Cells were then placed at 4°C for 30 min to allow detachment from temperature-sensitive plates. Cells (1 3 10 6 per tube) were collected in polystyrene Falcon tubes (BD Biosciences), washed with FACS buffer, collected with a BD FACSCalibur (BD Biosciences) and analyzed using FlowJo software (Tree Star).
Cytokine analysis
After treatment with hormones and LPS (5 lg ml À1 ) for 48 h (as described in Hormone Treatment and Stimulation of Bone Marrow Cultures), supernatants (140 ll total volume per condition) were collected from cultured cells. TNF-a, IL-1b and IL-10 secretion were determined using the Searchlight multiplex array analysis service provided by Pierce Biotechnology, Inc. (Woburn, MA, USA). Timecourse studies (data not shown) showed little production of cytokines by LPS-matured cells after 6 h, moderate levels of cytokine production at 24 h and maximal production at 48 h. Levels of cytokines began to decrease at 72 h after LPS stimulation. This was similar to results reported in a previous study (34) . Therefore, 48 h was used for cytokine production experiments and to compare cellular function under the various conditions.
Surface marker expression analysis of cultured BMDCs
Cultured cells (1 3 10 6 per tube) treated with progesterone or dexamethasone were collected in polystyrene Falcon tubes (BD Biosciences) and prepared for FACS analysis as previously described (see Analysis of Hormone Receptor Expression). Collected cells were pelleted followed by incubation with 10 ll FITC-labeled anti-rat CD11c (eBioscience) or Armenian hamster IgG (isotype control), PE-labeled antirat CD80 or mouse IgG (isotype control), PE-labeled anti-rat MHC class II RT1B or mouse IgG (isotype control) and PerCP-labeled anti-rat MHC class II RT1B or mouse IgG (isotype control). All antibodies except CD11c were from BD PharMingen. Cells were collected with a BD FACSCalibur (BD Biosciences) and analyzed using FlowJo software (Tree Star).
DC capacity to stimulate naive T lymphocytes
Capacity of LPS-matured, cultured BMDCs treated with progesterone to stimulate T cell proliferation was assessed by mixed leukocyte reaction using T cells from spleens of allogeneic, female Fischer rats housed in the same cage. Lymphocytes were enriched from rat splenocytes using a magnetic pan T cell (OX52) antibody and CD4
+ cell-specific antibody (both from Miltenyi Biotec, Auburn, CA, USA) according to the manufacturer's instructions. Briefly, cells were incubated with pan T cell antibodies at 4°C for 20 min and passed through the pre-moistened magnetic column using the QuadroMACS magnetic cell separation system for positive selection of the OX52 + T cells. Positively selected cells were then incubated with CD4 antibodies at 4°C for 20 min and placed in a separate pre-moistened magnetic column using the QuadroMACS system to isolate OX52 + CD4 + T cells by positive selection. Preparations were consistently 90-95% CD4 + as assessed by flow cytometry. Allogeneic T cells were labeled with a 10-lM solution of 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE) in PBS (250 ll total) and incubated at 37°C/5% CO 2 for 10 min. Cells were washed and centrifuged to remove excess CFSE. LPS-matured, cultured BMDCs were incubated for 24 h with CFSE-labeled T cells (1:10 DC to T cell) at 37°C/5% CO 2 for 96 h. Mixed leukocyte reaction was performed with responders and stimulators in the presence of progesterone at different concentrations. T cells not incubated with DCs served as a control. Naive T lymphocyte proliferation was assessed after 96 h incubation with stimulator cells. Cells were collected with a BD FACSCalibur (BD Biosciences) and analyzed using FlowJo software (Tree Star).
Statistical analysis
For all statistical analysis, the level of significance was set at a probability of not >0.05 to be considered significant. Data are presented as mean values 6 standard deviations. Data analysis was done using Student's t-test. IC 50 was determined using a growth formula that predicts exponential growth using existing data.
Results
Cultured DCs express steroid hormone receptors
In order to know whether progesterone could act directly on cultured DCs, it was important to determine the expression of PR in cultured cells. Immature CD11c + BMDCs were examined for the expression of the PR as well as the GR, a steroid hormone receptor well known for its immunosuppressive effects on immune cells, using FACS analysis and fluorescent microscopy (Fig. 1) . PR was found to be expressed in ;60% of cultured bone marrow DCs. Proportions of cells expressing these hormone receptors were similar to that of freshly isolated DCs from bone marrow and spleens (data not shown). Cultured cells were then treated with progesterone or dexamethasone (glucocorticoid) to identify any differences in expression of the hormone receptors at the transcriptional level with receptor activation. While GR expression increased significantly (P < 0.05) in response to LPS, PR expression did not ( Fig. 2A and C) . In contrast, PR expression increased significantly, ;25-fold over control levels, at the highest concentrations of progesterone tested with or without LPS treatment ( Fig. 2A and B) , while GR expression was not as dramatically affected by treatment with progesterone or dexamethasone (Fig. 2C and D) . A timecourse experiment (6, 24, 48 and 72 h) using the various conditions showed that 24 h post-treatment provided the maximum response for the genes analyzed.
Antigen uptake ability by immature DCs is not significantly affected by progesterone
One of the major functions of DCs is the capacity to take up antigenic material when these cells are in an immature state. Immature cells scavenge the environment for antigenic particulates that can be taken up using their F c receptors and, once the antigen is engulfed, these cells have the capacity to process antigen for presentation to naive lymphocytes following stimulation with maturation agents. In order to determine the effects of progesterone on antigen uptake by immature BMDCs, cells were cultured in the presence of progesterone or dexamethasone with FITC-dextran, which served as an antigen, to assess the effects of these steroid hormones on the functionality of immature BMDCs. Antigen uptake was assessed using flow cytometry (Table 1) . Similar numbers of cultured DCs were able to take up FITC-dextran in the absence of progesterone or in concentrations ranging from that seen during the follicular and luteal phases of the menstrual cycle (10 À10 and 10 À9 M), with the highest numbers of cells taking up antigen at pregnancy levels (10 À7 M). Statistically significant effects of progesterone on the number of immature DC taking up antigenic material were identified only at the pregnancy-associated concentrations of the hormone. Treatment of immature, cultured BMDCs with dexamethasone resulted in an increase in the proportions of cells taking up antigenic peptide. In addition, there was a significant decrease in viability of cells treated with dexamethasone at the 10 À7 M concentration, which might account for the similar proportions of cells taking up antigen at the 10 À8 M concentration.
Progesterone suppresses pro-inflammatory responsepromoting cytokine production in cultured BMDCs
In order to examine the effects of progesterone on mature BMDCs, we first determined the ability of these cells to pro- duce cytokines. For these experiments, secreted levels of cytokines that promote or inhibit pro-inflammatory responses were measured in the presence of progesterone or dexamethasone. The bacterial cell wall LPS from E. coli was used as an activating agent for the BMDCs. Maximal cytokine production was observed between 24 and 48 h, and cytokine levels began to drop at 72 h (data not shown). Therefore, 48-h timepoints were used for analysis of cytokine production by cultured cells. As shown in Fig. 3(A) , progesterone in a dose-dependent manner (IC 50 ¼ 1.3 3 10 À8 ) suppressed the ability of cultured, mature BMDCs to produce TNF-a, a cytokine that is important in inducing pro-inflammatory immune responses. TNF-a is a known target gene for PR; therefore, we also examined another pro-inflammatory response-promoting cytokine to see if progesterone would have effects on secretion of other cytokines. Figure 3(C) shows that progesterone also suppressed secretion of the pro-inflammatory response-promoting cytokine IL-1b (IC 50 ¼ 1.5 3 10 À9 ). The immunosuppressive hormone dexamethasone also suppressed TNF-a in a dose-dependent manner (IC 50 ¼ 6.8 3 10 À10 ), as expected (Fig. 3B) . Dexamethasone suppression of TNF-a production was more potent compared with progesterone, both in terms of maximal suppression and IC 50 dose, although progesterone did not fully suppress TNF-a production at any dose examined. In order to determine if this effect was mediated through the steroid hormone receptors, cells were also treated with the PR and GR antagonist RU486. RU486 completely prevented progesterone suppression of TNF-a and IL-1b secretion, indicating that this inhibition is most likely mediated through PR. RU486 added to cultures treated with dexamethasone did not completely reverse dexamethasone-mediated cytokine suppression, suggesting that higher concentrations of RU486 might be needed for this effect. In order to determine Fig. 3 . LPS-induced production of pro-inflammatory response-promoting cytokines TNF-a and IL-1b by cultured rat BMDCs treated with progesterone or dexamethasone. BMDCs matured using LPS from Escherichia coli (5 lg ml
À1
) and treated with progesterone showed a dosedependent effect on secretion of TNF-a (A) and IL-1b (C) at 48 h after treatment. Similar dose-dependent effects on TNF-a secretion were also shown upon treatment of BMDCs with dexamethasone (B). Cells not treated with LPS or only treated with hormones or RU486 served as a control. Cells treated with ethanol alone (data not shown) demonstrated similar results as cells not treated with LPS. Real-time PCR showed that this dosedependent effect on BMDCs by progesterone was also at the level of transcription (D). Data are presented as mean values 6 standard deviations. Data analysis was done using Student's t-test. *P < 0.05.
whether differences in expression of TNF-a resulted from changes at the transcriptional level, we used real-time RT-PCR to measure changes in expression of TNF-a at the level of transcription in response to progesterone (Fig. 3D ). Progesterone was able to decrease expression of TNF-a mRNA in a dose-dependent manner. We also examined the ability of progesterone to affect BMDC production of IL-10, a cytokine believed to inhibit pro-inflammatory responses (35) . As shown in Fig. 4(A) , progesterone did not show a dosedependent effect on secretion of IL-10 by these cells. Dexamethasone treatment of cultured BMDCs did induce a dose-dependent increase in IL-10 production (Fig. 4B) , which is consistent with the known anti-inflammatory effects of this glucocorticoid hormone. These results indicate that progesterone is able to directly inhibit production of proinflammatory response-promoting cytokines (TNF-a and IL-1b) without affecting production of pro-inflammatory responseinhibiting cytokines (IL-10) by these cells.
Progesterone down-regulates BMDC expression of cellsurface markers that stimulate naive lymphocytes
We next investigated the effects of progesterone on the ability of mature, LPS-activated BMDCs to express cell-surface markers that are important for stimulation of naive lymphocytes. MHC class II molecules and co-stimulatory molecules are up-regulated during maturation of DCs and are important to provide the first and second signals, respectively, to stimulate naive lymphocytes. Therefore, we measured expression of the MHC class II molecule RT1B, one of the most common MHC class II molecules expressed by immature and mature rat DCs (32) , and the co-stimulatory molecule CD80 on mature BMDCs with progesterone treatment after 48 h stimulation, as this was the same timepoint used for measurement of cytokine production. As shown in Fig. 5 , LPS treatment of cultured BMDCs up-regulated expression of CD80 and RT1B. Addition of progesterone resulted in a dose-dependent down-regulation of expression of CD80 in cultured BMDCs at all concentrations of the steroid hormone assessed (Fig. 5A) , including levels commensurate with physiological (luteal phase) levels of the hormone (10 À9 M). As expected, treatment of BMDCs with dexamethasone also down-regulated CD80 in a dose-dependent manner (Fig. 5C ). Progesterone suppressed expression of RT1B, but only at the highest dose of progesterone examined (10 À7 M) (Fig.  5B ). This concentration is consistent with the levels of progesterone seen during pregnancy. In contrast, dexamethasone suppressed the expression of RT1B at all levels examined (Fig. 5D ).
Progesterone prevents BMDC activation of T cells
One of the hallmarks of mature DC function is their capacity to stimulate naive T lymphocytes and induce proliferation of these cells. In order to determine whether the effects of progesterone on cultured, LPS-activated BMDCs would affect the ability of these cells to stimulate T cells, we co-cultured BMDCs with CD4
+ allogeneic T cells in the presence of LPS and concentrations of progesterone seen during the luteal phase of the menstrual cycle and during pregnancy. As shown in Fig. 6, CD4 + allogeneic T cells cultured in the presence of LPS-activated, mature BMDCs showed an increase in proliferation of naive T lymphocytes. Addition of progesterone at increasing concentrations (10 -9 and 10 -7 M) resulted in a dose-dependent decrease in T cell proliferation, indicating that progesterone is able to inhibit the ability of mature BMDCs to stimulate naive T lymphocyte activation.
Discussion
DCs are immune cells that play an important role in mounting strong host immune responses to pathogens and serve as the interface between innate and adaptive immunity (36) . Factors that control these cells can ultimately drive the direction of immune responses or prevent an immune response from being mounted. Progesterone is a steroid hormone present in pregnant and non-pregnant females in plasma concentrations ranging from 10 À9 M in the non-pregnant state (luteal phase of menstrual cycle) to 10 À7 M during pregnancy. While progesterone is thought to affect the Fig. 4 . Production of the pro-inflammatory response-inhibiting cytokine IL-10 by cultured, mature rat BMDCs after 48 h treatment with LPS. BMDCs matured using LPS from Escherichia coli(5 lg ml
À1
) and treated with progesterone (A) do not show dose-dependent effects on IL-10 secretion. Treatment with dexamethasone (B) shows an expected dose-dependent increase on IL-10 production by these cells. Data are presented as mean values 6 standard deviations. Data analysis was done using Student's t-test. *P < 0.05. severity of certain autoimmune diseases (37) (38) (39) (40) , the exact mechanisms of its effects on these diseases have not been thoroughly investigated. In this study, we examined the effects of progesterone concentrations spanning those found in pregnant and non-pregnant females to ascertain its effects on cultured rat BMDC function. 6 . LPS-matured, cultured BMDC ability to stimulate T cell proliferation. BMDCs matured using LPS from Escherichia coli(5 lg ml
) and treated with progesterone were incubated with CFSE-labeled CD4 + allogeneic T cells from female rats. Progesterone was washed from cultures prior to addition of T cells to ensure a DC-specific effect of progesterone on T cell proliferation. Results showed a dose-dependent effect on the ability to stimulate proliferation of CFSE-labeled CD4 + T cells only at the pregnancy-associated concentrations of progesterone (data are representative of four separate experiments).
Progesterone had the greatest effect on functional capacity of LPS-activated, mature BMDCs. Progesterone, even at physiological concentrations, suppressed LPS-induced secretion of the pro-inflammatory response-promoting cytokines TNF-a and IL-1b. Progesterone also inhibited the ability of mature BMDCs to express cell-surface markers, including the co-stimulatory molecule CD80 and the MHC class II molecule RT1B, which are associated with DC activation. The dose-dependent effect of progesterone on TNF-a production is consistent with previous studies showing that TNF-a is one of the target genes of PR in macrophages (41) . Dexamethasone, a known immunosuppressive agent, was more potent than progesterone in suppressing TNF-a and IL-1b secretion. The magnitude of suppression of proinflammatory response-promoting cytokines by progesterone was ;100-fold less than that of dexamathasone. Furthermore, the PR and GR antagonist RU486 was able to prevent progesterone-induced inhibition of TNF-a and IL-1b production by BMDCs and inhibited some of the suppressive effects of dexamethasone, indicating that the effects of these hormones on cultured BMDCs are mediated through their receptors. Progesterone down-regulated expression of CD80 on cultured BMDCs at all concentrations examined, but only down-regulated RT1B expression at the highest concentrations of progesterone, commensurate with pregnancy. Progesterone also decreased the capacity of cultured BMDCs to stimulate allogeneic T lymphocytes in a dosedependent manner. These results suggest that progesterone could play a role in preventing DC promotion of pro-inflammatory responses and activation of naive lymphocytes or could drive tolerogenic responses by these cells, in both non-pregnant and pregnant states.
In contrast to the effects of progesterone on mature BMDCs, progesterone had a weaker effect on the functional capacity of immature BMDCs to take up antigen. As there was essentially no effect of progesterone on immature BMDC activity, RU486 was not added to the cultures to identify its effect on reversing progesterone modulation of immature DC activity. A significant effect was observed only at the highest concentrations of progesterone, similar to levels seen during pregnancy. This effect of progesterone at pregnancy-associated concentrations is consistent with the previously reported non-genomic effects of progesterone on endometrial stromal cells (42) . The weaker effect on immature BMDC capacity may be related to the specific genes that are targeted by progesterone when it functions as a transcription factor and may not include genes that affect the capacity of these cells to take up antigen. Progesterone also had no effect on production of the proinflammatory response-inhibiting cytokine IL-10. Our findings are in contrast to a report by Huck et al. (43) that showed an increase in IL-10 levels in response to progesterone treatment of human PBMCs. Possible factors contributing to this discrepancy include species differences, differences in response of different cell types and the fact that responses of cells from male and female subjects were analyzed together in this study. Similarly, species differences and combining data from male and female animals could also account for the discrepancy between our findings and the increased intracellular IL-10 production in response to progesterone in DCs from mouse spleens reported by Yang et al. (44) .
Taken together, our findings indicate that progesterone can inhibit pro-inflammatory immune responses by limiting the functional capacity of mature DCs in rats at concentrations of the hormone similar to pregnant and non-pregnant states. These findings suggest that progesterone should be considered as one of several factors contributing to the shift away from T h 1 responses during pregnancy and also could account for some of the differences in autoimmune susceptibility in females in general. Finally, since DCs play an important role in host-pathogen responses, these data may have implications for the use of progesterone and PR agonists in inflammatory or infectious conditions.
